

RECEIVED

JAN 15 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D. C. 20231.

Date:

Judith Davis

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jiangchun Xu
Application No. : 09/347,496
Filed : July 2, 1999
For : COMPOUNDS FOR IMMUNOTHERAPY AND DIAGNOSIS
OF COLON CANCER AND METHODS FOR THEIR USE
Examiner Jehanne Souaya
Art Unit 1655
Docket No. 210121.471C1
Date November 27, 2001

DECLARATION OF SUSAN HARLOCKER, PH.D.

Commissioner of Patents
Washington D.C. 20231

The undersigned, Susan Harlocker, Ph.D., hereby declares:

1. I am a Scientist and Project Group Leader at Corixa Corporation, the assignee of the subject application. The following analysis was performed by me.
2. A nucleotide sequence alignment of SEQ ID NO:21 and L1-Cadherin (GenBank Accession Number NM_004063), was made and is shown in Figure 1. These sequences have structural similarity as is evidenced by the alignment of SEQ ID NO:21 over the entirety of its length to the sequence of L1-Cadherin from nucleotides 1666-2011. As is shown in Figure 1, with the exception of a single n at nucleotide 1755 and an additional a at nucleotide 2009 near the end of SEQ ID NO:21, the 2 sequences are 100% identical over the length of SEQ ID NO:21.

3. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful, false statements, and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Susan Harlocker
Susan Harlocker, Ph.D.

11/27/01
Date

C:\NrPortbl\iManage\JULIEU\236637_1.DOC

[illegible]

ran_004063.SEQ(1>3654)

1